Thiocolchicoside
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Thiocolchicoside: From Muscle Spasm to Insomnia
One-Sentence Summary
Thiocolchicoside is a semi-synthetic muscle relaxant traditionally used to treat painful muscle spasms associated with spinal and musculoskeletal disorders. The TxGNN model predicts it may be effective for Insomnia (disease), but this direction is currently supported mainly by a computational prediction score — only 1 loosely related clinical trial and no directly relevant literature have been identified so far.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Muscle spasm associated with spinal/musculoskeletal disorders (official regulatory indication text not available in this Evidence Pack) |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Thiocolchicoside belongs to the muscle relaxant drug class, acting on GABA-A and glycine receptors in the central nervous system to reduce muscle hypertonia and spasm. Its efficacy in musculoskeletal spasm has been established through long-standing clinical use in multiple markets.
Mechanistically, GABA-A and glycine receptor modulation is also implicated in sleep regulation and central nervous system inhibition, which could theoretically provide a plausible — but currently unproven — link between Thiocolchicoside’s known muscle-relaxant/sedative properties and a potential effect on insomnia. However, this link has not yet been substantiated by disease-specific clinical or literature evidence in the data reviewed.
The one clinical trial retrieved for this prediction (NCT06791434) is a Phase 4 study of dry needling as an add-on therapy for myofascial low back pain — it does not investigate insomnia and does not mention Thiocolchicoside directly relevant outcomes for sleep. This suggests the current evidence base for the insomnia prediction is essentially model-driven rather than clinically validated.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06791434 | Phase 4 | Completed | 156 | Evaluated dry needling as an add-on to conventional treatment (including muscle relaxants and NSAIDs) for myofascial low back pain. Not directly focused on insomnia; relevance to this indication is unconfirmed (relevance grading pending, no reasoning recorded). |
Literature Evidence
Currently no related literature available.
India Market Information
Thiocolchicoside is currently not marketed in India according to this Evidence Pack, with 0 registered licenses/products on record.
Safety Considerations
Please refer to the package insert for safety information.
(Note: Key warnings, contraindications, and drug interaction data are flagged as a Blocking-severity data gap in this Evidence Pack and must be resolved before any safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the insomnia prediction is essentially model-only (L5) — the single associated clinical trial is not topically relevant, and no supporting literature exists. Combined with a Blocking-severity gap in TFDA/DCGI label safety data (warnings and contraindications unavailable) and the drug’s current unmarketed status in India, there is insufficient basis to advance this candidate at this time.
To proceed, the following is needed:
- Official package insert data (warnings, contraindications) — currently blocking safety review
- Confirmed mechanism of action (MOA) via DrugBank or primary literature
- Disease-specific clinical trials or publications directly studying Thiocolchicoside for insomnia or sleep-related outcomes
- Confirmation of regulatory registration status/pathway in India, given the drug is currently unmarketed
Note: A second, lower-confidence candidate (alcohol withdrawal delirium, TxGNN score 99.21%, rank 12,052) was also predicted but has zero supporting clinical trials or literature — it is not evaluated further in this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.